English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

TNF-a, a potent proinflammatory cytokine, is generated in a precursor form called transmembrane (m)TNF-a that is expressed as a type II polypeptide on the surface of certain cells. mTNF-a was shown to act both as a ligand by binding to TNF-a receptors, as well as a receptor that transmits outside-to-inside (reverse) signals back into the mTNF-a–bearing cells. In this study, we show that nonactivated macrophages express basal levels of mTNF-a and respond to anti–TNF-a Abs by triggering the MAPK kinase 4 signaling pathway. The pathway induces TGF-b. Based on inhibitory experiments, the production of TGF-b1 is regulated via Jun kinases, whereas that of other TGF-bs is regulated via p38 MAPKs. Exposure to LPS further induced the expression of mTNF-a, and triggering of mTNF-a strongly suppressed the LPS-induced proinflammatory response. Neutralizing TGF-b by Abs prevented the mTNF-a–mediated suppression of LPS-induced proinflammatory cytokine formation, indicating that the immunesuppressive effect of mTNF-a is mediated via TGF-b. Although apoptotic cells are also known to suppress LPS-induced proin- flammatory cytokine formation in macrophages by upregulating TGF-b, we show that they do not use the mTNF-a signaling pathway. Because TGF-b possesses a wide range of immune-suppressive effects, our data indicate that upregulation of TGF-b synthesis by those TNF-a–targeting molecules, which are able to trigger mTNF-a, might contribute to their therapeutic effect in the treatment of certain inflammatory diseases such as Crohn’s disease, Wegener’s granulomatosis, or sarcoidosis. Additionally, none of the TNF-a–targeting molecules is expected to interfere with the immune-silencing effects of apoptotic cells

zenodo (cern european organization for nuclear research)

Transmembrane TNF-a Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-b: Therapeutic Implications